LXEO
insider transactionsLexeo Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-59.6K
0 buy · 59.6K sell
Net value · 90d
-$336.7K
$0 in · $336.7K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
3
0 buy · 59.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Chief Operating Officer
$6.6K
1.3K sh · $5.07
Own -1%
-
Sell·S
Chief Executive Officer
$16.9K
3.3K sh · $5.06
Own -1%
-
Grant·A
Director
$0
50.0K sh
Own New
-
Sell·S
Chief Executive Officer · 10b5-1
$313.1K
55.0K sh · $5.69
Own -14%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 18, 2026 | Jose Manuel Otero | Sell S | 1.3K | $6.6K |
| May 18, 2026 | Richard Nolan Townsend KEY | Sell S | 3.3K | $16.9K |
| Apr 28, 2026 | Laura Sepp-Lorenzino | Grant A | 50.0K | $0 |
| Apr 6, 2026 | Richard Nolan Townsend KEY 10b5-1 | Sell S | 55.0K | $313.1K |
About LXEO insider trading
This page tracks insider transactions for Lexeo Therapeutics, Inc. (LXEO) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.